171 related articles for article (PubMed ID: 16620672)
1. [The detection of protein expression of clusterin and Ki-67 and the status of cell apoptosis in bladder transitional cell carcinoma].
Chen W; Xie D; Luo JH; Wang CX; Tao Y; Zheng KL; Mei H
Zhonghua Wai Ke Za Zhi; 2006 Jan; 44(2):111-4. PubMed ID: 16620672
[TBL] [Abstract][Full Text] [Related]
2. [The clinical significance of expression and amplification of FGF3 in bladder transitional cell carcinoma].
Zhang YH; Xie D; Luo JH; Chen W; Chen LW; Xu QC
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(36):2556-9. PubMed ID: 17198565
[TBL] [Abstract][Full Text] [Related]
3. [The clinico-pathological significance of protein expression of PAK1 in bladder transitional cell carcinoma].
Zhang YH; Xie D; Luo JH; Chen W; Chen LW; Xu QC; Liu GY; Ma HB; Lin WQ
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2710-3. PubMed ID: 18167251
[TBL] [Abstract][Full Text] [Related]
4. [Correlation of clusterin expression to prognosis of bladder carcinoma].
Luo JH; Xie D; Chen W; Dai YP; Li XF; Tao Y; Zheng KL
Ai Zheng; 2005 Jun; 24(6):743-7. PubMed ID: 15946493
[TBL] [Abstract][Full Text] [Related]
5. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression.
King ED; Matteson J; Jacobs SC; Kyprianou N
J Urol; 1996 Jan; 155(1):316-20. PubMed ID: 7490878
[TBL] [Abstract][Full Text] [Related]
6. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
[TBL] [Abstract][Full Text] [Related]
7. Extent of spontaneous apoptosis in gastric cancer: relation to proliferative index, p53 expression, CD 34 expression and histopathological features.
Jesionek-Kupnicka D; Tenderenda M; Rutkowski P
J Exp Clin Cancer Res; 2002 Sep; 21(3):371-5. PubMed ID: 12385580
[TBL] [Abstract][Full Text] [Related]
8. Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma.
Xie D; Lau SH; Sham JS; Wu QL; Fang Y; Liang LZ; Che LH; Zeng YX; Guan XY
Cancer; 2005 Jan; 103(2):277-83. PubMed ID: 15578711
[TBL] [Abstract][Full Text] [Related]
9. [Smad4 and TGF-beta1 expression and clinical significance in bladder transitional cell carcinoma].
Tang ZY; Yang LY; Zhang YJ; Peng KL; Qi L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 31(3):363-6. PubMed ID: 16859125
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of clusterin in human hepatocellular carcinoma.
Kang YK; Hong SW; Lee H; Kim WH
Hum Pathol; 2004 Nov; 35(11):1340-6. PubMed ID: 15668890
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
12. [Immunohistochemical study of p53 and Ki-67 antigen expression in bladder carcinoma].
Yuge F; Hirakata H; Igarashi H; Kodama M; Kawata N; Takimoto Y
Hinyokika Kiyo; 1999 Jul; 45(7):453-6. PubMed ID: 10466059
[TBL] [Abstract][Full Text] [Related]
13. Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma.
Krüger S; Mahnken A; Kausch I; Feller AC
Urology; 2006 Jan; 67(1):105-9. PubMed ID: 16413343
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder.
Fernández MI; Bolenz C; Trojan L; Steidler A; Weiss C; Alken P; Grobholz R; Michel MS
Eur Urol; 2008 Mar; 53(3):571-8. PubMed ID: 17804149
[TBL] [Abstract][Full Text] [Related]
15. [Expression of Caspase-3 and Bcl-2 in bladder transitional carcinoma and their significance].
Shen HW; Yi L; Wang XM; Yao MJ; Deng JW; Fang JZ; Li MN
Ai Zheng; 2004 Feb; 23(2):181-4. PubMed ID: 14960240
[TBL] [Abstract][Full Text] [Related]
16. Novel p53/p130 axis in bladder tumors.
Mudryj M; Reay E; Beckett L; Dandekar S; deVere White R; Gandour-Edwards R
Urology; 2007 Sep; 70(3):608-12. PubMed ID: 17905135
[TBL] [Abstract][Full Text] [Related]
17. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
18. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension.
Kurahashi T; Muramaki M; Yamanaka K; Hara I; Miyake H
BJU Int; 2005 Oct; 96(6):895-9. PubMed ID: 16153225
[TBL] [Abstract][Full Text] [Related]
19. Combined-modality treatment and organ preservation in bladder cancer. Do molecular markers predict outcome?
Weiss C; Rödel F; Wolf I; Papadopoulos T; Engehausen DG; Schrott KM; Sauer R; Rödel C
Strahlenther Onkol; 2005 Apr; 181(4):213-22. PubMed ID: 15827690
[TBL] [Abstract][Full Text] [Related]
20. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
Zhou JT; Cai ZM; Li NC; Na YQ
Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
